Literature DB >> 8456440

HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype.

N de Vries1, K S Rønningen, M G Tilanus, A Bouwens-Rombouts, R Segal, T Egeland, E Thorsby, L B van de Putte, C Brautbar.   

Abstract

Rheumatoid arthritis (RA) is associated with the HLA-DR4 cellular subtypes Dw4 and Dw14 in Caucasians, with Dw15 in Japanese, and possibly with HLA-DR1 in Israeli Jews. Sequencing studies in Caucasians have shown that these molecules share a common amino acid sequence in the third hypervariable region of the DR molecule (AA 67-74: LLEQRRAA or LLEQKRAA), suggesting that this sequence is primarily associated with RA. An important argument in favor of this shared-epitope hypothesis has been the reported association between DR1 and RA in Israeli Jews. However, a later report did not confirm this association, and cellular typing showed that Israeli DR1 consists of three or more subtypes, suggesting that new subtypes might be present. Since no sequencing data on Israeli HLA-DR1 genes have been reported, we sequenced the first domain (AA 10-91) of the DRB1 gene in 12 DR1-positive Israeli RA patients, 5 healthy controls and a homozygous typing cell (HTC), defining the major Jewish cellular HLA-DR1 subtype. DRB1*0102 (DR1 Dw20) was found in 8 RA patients, 3 controls and the HTC "LVA". DRB1*0101 (DR1 Dw1) was found in 4 RA patients and 2 controls. No other DR1 subtypes were encountered. In all 20 DR1 haplotypes, the DRB1*0101 or 0102 allele was associated with DQA1*0101 and DQB1*0501, being identical to the Caucasian DR1 haplotypes. Thus, at the sequence level, we found no basis for the reported extensive cellular heterogeneity of DR1 in the Israeli population.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456440     DOI: 10.1111/j.1399-0039.1993.tb01973.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  8 in total

1.  HLA-DRB1 the notorious gene in the mosaic of autoimmunity.

Authors:  María-Teresa Arango; Carlo Perricone; Shaye Kivity; Enrica Cipriano; Fulvia Ceccarelli; Guido Valesini; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Ethnicity may be a reason for lipid changes and high Lp(a) levels in rheumatoid arthritis.

Authors:  Mustafa Cesur; Zeynep Ozbalkan; Mehtap Akcil Temel; Yaşar Karaarslan
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

3.  Association of biomarkers of inflammation and HLA-DRB1 gene locus with risk of developing rheumatoid arthritis in females.

Authors:  Biljana Klimenta; Hilada Nefic; Nenad Prodanovic; Radivoj Jadric; Fatima Hukic
Journal:  Rheumatol Int       Date:  2019-08-26       Impact factor: 2.631

4.  Sex influences on the penetrance of HLA shared-epitope genotypes for rheumatoid arthritis.

Authors:  J M Meyer; J Han; R Singh; G Moxley
Journal:  Am J Hum Genet       Date:  1996-02       Impact factor: 11.025

5.  Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis.

Authors:  Ori Elkayam; Refael Segal; Dan Caspi
Journal:  Rheumatol Int       Date:  2003-06-17       Impact factor: 2.631

6.  Interaction between smoking and HLA-DRB1*04 gene is associated with a high cardiovascular risk in Brazilian Amazon patients with rheumatoid arthritis.

Authors:  Narjara de Oliveira Boechat; Mauricio Morish Ogusku; Antonio Luiz Boechat; Aya Sadahiro
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

Review 7.  Identification of rheumatoid arthritis biomarkers based on single nucleotide polymorphisms and haplotype blocks: A systematic review and meta-analysis.

Authors:  Mohamed N Saad; Mai S Mabrouk; Ayman M Eldeib; Olfat G Shaker
Journal:  J Adv Res       Date:  2015-02-04       Impact factor: 10.479

Review 8.  Current Understanding of an Emerging Role of HLA-DRB1 Gene in Rheumatoid Arthritis-From Research to Clinical Practice.

Authors:  Tomasz Wysocki; Marzena Olesińska; Agnieszka Paradowska-Gorycka
Journal:  Cells       Date:  2020-05-02       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.